AR030093A1 - Sistema para la distribucion topica del gel - Google Patents

Sistema para la distribucion topica del gel

Info

Publication number
AR030093A1
AR030093A1 ARP010103660A ARP010103660A AR030093A1 AR 030093 A1 AR030093 A1 AR 030093A1 AR P010103660 A ARP010103660 A AR P010103660A AR P010103660 A ARP010103660 A AR P010103660A AR 030093 A1 AR030093 A1 AR 030093A1
Authority
AR
Argentina
Prior art keywords
composition
optionally
disorder
treatment
skin
Prior art date
Application number
ARP010103660A
Other languages
English (en)
Original Assignee
Dow Pharmaceuticals Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24535786&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR030093(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dow Pharmaceuticals Sciences filed Critical Dow Pharmaceuticals Sciences
Publication of AR030093A1 publication Critical patent/AR030093A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Abstract

Se provee una composicion que tiene una viscosidad inferior que alrededor de 15,000 cP y un pH entre alrededor de 3,0 y 9,0 para el tratamiento del trastorno de la piel en un sujeto. La composicion consiste esencialmente en (a) una cantidad terapéuticamente efectiva de al menos un compuesto util para el tratamiento del trastorno; (b) un polímero de ácido poliacrílico, levemente entrecruzado, farmacéuticamente aceptable compatible con el compuesto, (c) opcionalmente, un solvente miscible en agua (d) opcionalmente un conservante, (e) opcionalmente, un componente de fase oleosa y un surfactante adecuado, y (f) agua. La composicion es util para tratar un trastorno inflamatorio de la piel, acné, o rosácea. La composicion de baja viscosidad tiene la ventaja de ser administrada con más precision cuando se combina con un envase que administra la composicion en gotas.
ARP010103660A 2000-08-03 2001-07-31 Sistema para la distribucion topica del gel AR030093A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/632,508 US6387383B1 (en) 2000-08-03 2000-08-03 Topical low-viscosity gel composition

Publications (1)

Publication Number Publication Date
AR030093A1 true AR030093A1 (es) 2003-08-13

Family

ID=24535786

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103660A AR030093A1 (es) 2000-08-03 2001-07-31 Sistema para la distribucion topica del gel

Country Status (25)

Country Link
US (2) US6387383B1 (es)
EP (2) EP1304992B1 (es)
JP (1) JP4988129B2 (es)
KR (2) KR20080036246A (es)
CN (2) CN1460013B (es)
AR (1) AR030093A1 (es)
AT (1) ATE429922T1 (es)
AU (2) AU2001279002B2 (es)
BE (1) BE2013C060I2 (es)
BR (1) BR0113247A (es)
CA (1) CA2417646C (es)
CY (3) CY1109189T1 (es)
DE (1) DE60138549D1 (es)
DK (2) DK2052714T3 (es)
ES (2) ES2437321T3 (es)
FR (1) FR14C0053I1 (es)
HK (1) HK1125847A1 (es)
LU (1) LU92401I2 (es)
MX (1) MXPA03001006A (es)
PL (1) PL213237B1 (es)
PT (2) PT2052714E (es)
RU (1) RU2251410C2 (es)
SI (2) SI2052714T1 (es)
WO (1) WO2002011683A1 (es)
ZA (1) ZA200301037B (es)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
ATE272391T1 (de) 1998-12-23 2004-08-15 Idea Ag Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
DK1031347T3 (da) 1999-01-27 2002-07-08 Idea Ag Transnasal transport/immunisering med meget tilpasselige bærere
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
MXPA02000053A (es) * 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7060732B2 (en) * 2000-12-12 2006-06-13 Imaginative Research Associates, Inc. Antibiotic/benzoyl peroxide dispenser
US20060189552A1 (en) * 2000-12-12 2006-08-24 Mohan Vishnupad Dispenser for dispensing three or more actives
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
WO2002089743A2 (en) 2001-05-09 2002-11-14 The Regents Of The University Of Michigan Use of compositions for treating rosacea
US7368122B1 (en) * 2002-03-08 2008-05-06 Dow Pharmaceutical Sciences Skin cream
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
NZ537360A (en) 2002-06-25 2006-09-29 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
US20040171561A1 (en) * 2002-09-03 2004-09-02 Popp Karl F. Topical formulations for treatment of rosacea
US20040167223A1 (en) * 2002-09-03 2004-08-26 Popp Karl F. Topical antibacterial formulations
US6906014B2 (en) * 2002-09-10 2005-06-14 Permatex, Inc. Stabilized topical composition
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US7208485B2 (en) * 2003-01-13 2007-04-24 Chemagis Ltd. Crystalline forms of halobetasol propionate
MXPA05007722A (es) 2003-01-24 2006-01-31 Connetics Australia Pty Ltd Espuma de fosfato de clindamicina.
US20060135607A1 (en) * 2003-02-07 2006-06-22 Mochida Pharmaceutical Co., Ltd. Drug for improving prognosis for subarachnoid hemorrhage
US20040202726A1 (en) * 2003-04-10 2004-10-14 Deshay Samuel L. Topical blood pressure composition
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
TW200510412A (en) 2003-08-12 2005-03-16 3M Innovative Properties Co Oxime substituted imidazo-containing compounds
EP1660101A4 (en) * 2003-08-21 2010-02-24 Access Pharma Inc LIQUID FORMULATIONS FOR THE PREVENTION AND TREATMENT OF SLAUGHTER DISEASES AND DISORDERS
CA2536136C (en) 2003-08-27 2012-10-30 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP2007504269A (ja) 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Ｃｄ５＋ｂ細胞リンパ腫の治療方法
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
MY144021A (en) * 2003-09-19 2011-07-29 Drugtech Corp Pharmaceutical delivery system
DE60317579T2 (de) * 2003-09-23 2008-09-18 Akciju Sabiedriba "Olainfarm" Polymere 3,5-dimethyl-1-adamantylammoniumsalze und deren verwendung in form von virustatika
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
JP5043435B2 (ja) 2003-10-03 2012-10-10 スリーエム イノベイティブ プロパティズ カンパニー アルコキシ置換イミダゾキノリン
US20050095215A1 (en) * 2003-11-03 2005-05-05 Popp Karl F. Antimicrobial shampoo compositions
AU2004291122A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
CN1906193A (zh) 2003-11-14 2007-01-31 3M创新有限公司 肟取代的咪唑环化合物
AR046781A1 (es) 2003-11-25 2005-12-21 3M Innovative Properties Co Derivados de imidazoquinolinas. composiciones farmaceuticas.
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
WO2005066169A2 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
US20050139808A1 (en) * 2003-12-30 2005-06-30 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution and process for producing same
AU2004311432A1 (en) * 2003-12-30 2005-07-21 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution, processes for producing same and methods of using the same
US20050147570A1 (en) * 2004-01-06 2005-07-07 Nordsiek Michael T. Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
WO2005094531A2 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US20050255131A1 (en) * 2004-05-11 2005-11-17 Mohan Vishnupad Clindamycin compositions and delivery system therefor
US20060014834A1 (en) * 2004-05-11 2006-01-19 Mohan Vishnupad Retinoid solutions and formulations made therefrom
US7662855B2 (en) * 2004-05-11 2010-02-16 Imaginative Research Associates, Inc. Retinoid solutions and formulations made therefrom
BRPI0511519A (pt) 2004-05-25 2007-12-26 Sansrosa Pharmaceutical Dev In método para tratar ou prevenir um distúrbio inflamatório da pele e os sintomas associados com ele, composição tópica adequada para tratar ou evitar os sintomas de um distúrbio inflamatório dermatológico, e, embalagem para uma composição tópica
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US8741332B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
US8741333B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
US8907153B2 (en) 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
FR2887149B1 (fr) * 2005-06-17 2007-08-03 Galderma Sa Procede de solubilisation du metronidazole
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
ITMI20041376A1 (it) * 2004-07-09 2004-10-09 Uni Campus Bio Medico Di Roma Metodo di preparazione di un sistema polimerico biocompatibile per il rilascio farmacologico in uso topico e impieghi di detto sistema
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
JP2008519764A (ja) * 2004-11-09 2008-06-12 イマジナティブ リサーチ アソシエィツ インコーポレーテッド レチノイド溶液及びそれからつくった調合物
US20080095722A1 (en) * 2004-11-12 2008-04-24 Idea Ag Extended Surface Aggregates in the Treatment of Skin Conditions
WO2006074003A2 (en) 2004-12-30 2006-07-13 3M Innovative Properties Company CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
JP2008530113A (ja) 2005-02-11 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド オキシムおよびヒドロキシラミン置換イミダゾ［４，５−ｃ］環化合物および方法
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
WO2006121429A1 (en) * 2005-05-06 2006-11-16 Imaginative Research Associates, Inc. Clindamycin compositions and delivery system therefor
CA2605341A1 (en) * 2005-05-09 2006-11-16 Drugtech Corporation Modified-release pharmaceutical compositions
ES2607454T3 (es) 2005-06-03 2017-03-31 Acrux Dds Pty Ltd Método y composición para el suministro transdérmico de testosterona
AR054805A1 (es) * 2005-06-29 2007-07-18 Stiefel Laboratories Composiciones topicas para el tratamiento de la piel
KR20080055797A (ko) * 2005-08-23 2008-06-19 닛산 가가쿠 고교 가부시키 가이샤 서방성 제제
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
JP2009522362A (ja) * 2006-01-05 2009-06-11 ドラッグテック コーポレイション 薬物送達システム
BRPI0620908A2 (pt) * 2006-01-05 2011-11-29 Drugtech Corp composição farmacêutica, sistema de distribuição antibacteriana e antifúngica vaginal e uso da composição farmacêutica
US9107844B2 (en) * 2006-02-03 2015-08-18 Stiefel Laboratories Inc. Topical skin treating compositions
CA2645073A1 (en) * 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
PL2206494T3 (pl) 2006-03-31 2016-06-30 Stiefel Res Australia Pty Ltd Spienialny żel zawiesinowy
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
BRPI0717769A2 (pt) 2006-10-17 2013-11-05 Nuvo Res Formulação de gel, método para o tratamento da osteoartrite em um indivíduo sofrendo de dor articular, e, uso de diclofenac de sódio
US8466128B2 (en) * 2007-01-30 2013-06-18 Cypress Pharmaceuticals, Inc. Hyaluronate compositions
US20080287373A1 (en) * 2007-05-17 2008-11-20 Popp Karl F Topical skin treating kits
US20080312245A1 (en) * 2007-06-12 2008-12-18 Longyan Xiao Methods and compositions for treating acne and other infectious diseases
WO2009036368A2 (en) 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
US20090098191A1 (en) * 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
JP2011500687A (ja) * 2007-10-18 2011-01-06 メディシス・ファーマシューティカル・コーポレーション 水性レチノイドおよび過酸化ベンゾイルゲル
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20090131386A1 (en) * 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
PL3354276T3 (pl) * 2007-11-13 2020-09-21 Meritage Pharma, Inc. Kompozycje do leczenia zapalenia przewodu pokarmowego
BRPI0822095A2 (pt) 2007-12-21 2014-10-07 Galderma Lab Inc Método para reduzir o sangramento e/ou hematoma em um paciente
US20090176719A1 (en) * 2008-01-07 2009-07-09 Liolabs Llc Compositions and methods for treating perioral dermatitis
MX2010010111A (es) * 2008-03-17 2010-12-15 Glenmark Pharmaceuticals Ltd Formulacion topica de dosis fija estable.
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
KR20110021888A (ko) * 2008-05-16 2011-03-04 갈데르마 리써어치 앤드 디벨로프먼트 여드름 관련 질환을 치료하기 위한 치료 요법
CN102056481A (zh) 2008-06-05 2011-05-11 陶氏制药科学公司 包含低浓度的在水和水混溶性有机溶剂中的悬浮液形式的过氧苯甲酰的局部药物制剂
EP2293777B1 (en) * 2008-06-24 2015-02-25 Intervet International B.V. Pharmaceutical transdermal compositions and method for treating inflammation in cattle
US20100105750A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
US9775802B2 (en) 2009-03-24 2017-10-03 Bausch & Lomb Incorporated Method for preparing suspensions of low-solubility materials
US20100247666A1 (en) * 2009-03-24 2010-09-30 Macleod Steven K Method for Preparing Suspensions of Low-Solubility Materials
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP3141246A1 (en) 2009-08-31 2017-03-15 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
AU2011231544B2 (en) 2010-03-26 2015-01-15 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
MX2012010824A (es) 2010-03-26 2012-10-10 Galderma Res & Dev Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema.
AU2011273509A1 (en) 2010-06-30 2013-06-13 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
WO2012001065A2 (en) 2010-06-30 2012-01-05 Galderma Research & Development Method for preventing or treating skin tumor
WO2012052479A2 (en) 2010-10-21 2012-04-26 Galderma S.A. Brimonidine gel compositions and methods of use
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
WO2013016072A1 (en) 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
WO2013019974A1 (en) 2011-08-02 2013-02-07 Medicis Pharmaceutical Corporation Compositions comprising a retinoid and a lincosamide antibiotic for use in treating rosacea
WO2013057580A1 (en) 2011-10-19 2013-04-25 Galderma Pharma S.A. Method for treating capillary hemangiomas
US9744168B2 (en) 2011-10-19 2017-08-29 Galderma Laboratories, Inc. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
UA109359C2 (xx) 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
RU2548714C2 (ru) * 2012-05-03 2015-04-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения угревой болезни и способ ее получения
US8962028B2 (en) 2012-10-18 2015-02-24 MiCal Pharmaceuticals LLC—H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company Topical steroid composition and method
RU2530644C2 (ru) * 2012-11-01 2014-10-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Противоугревая фармацевтическая композиция и способ ее получения
AU2014207618A1 (en) 2013-01-16 2015-08-06 Emory University Cas9-nucleic acid complexes and uses related thereto
AU2014326298B2 (en) 2013-09-26 2019-07-04 Galderma Holding SA Prostaglandin F2alpha and analogues thereof for treating atrophic cutaneous scarring
US20150250697A1 (en) * 2014-03-07 2015-09-10 The Procter & Gamble Company Personal Care Compositions and Methods of Making Same
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
US9012402B1 (en) * 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
CN104473865A (zh) * 2014-11-17 2015-04-01 重庆华邦制药有限公司 ***凝胶剂及其制备方法
EP4349414A2 (en) 2014-12-23 2024-04-10 Dyve Biosciences, Inc. Methods and formulations for transdermal administration
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
ES2812451T3 (es) 2015-06-18 2021-03-17 Bausch Health Ireland Ltd Composiciones tópicas que comprenden un corticosteroide y un retinoide para tratar la psoriasis
MX2018000421A (es) 2015-07-13 2018-05-17 Dr Reddy´S Laboratories Ltd Composiciones de retinoides topicos.
CN106474047A (zh) * 2015-08-27 2017-03-08 重庆华邦制药有限公司 一种对光稳定的***制剂
CN106474048A (zh) * 2015-08-27 2017-03-08 重庆华邦制药有限公司 一种质量更加稳定的***凝胶制剂
CN106474059A (zh) * 2015-08-27 2017-03-08 重庆华邦制药有限公司 一种质量更加稳定的***洗剂
WO2017172761A1 (en) 2016-03-28 2017-10-05 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
WO2018213310A1 (en) 2017-05-15 2018-11-22 Cornell University Device and system for repairing intervertebral disc herniation and methods of use
US10779525B2 (en) 2018-01-16 2020-09-22 Zin Research LLC Treatment compound and method of application for hoof or foot disease in animals
US10653656B2 (en) * 2018-04-05 2020-05-19 Bausch Health Ireland Limited Topical pharmaceutical compositions for treating skin conditions
US20200138822A1 (en) * 2018-11-06 2020-05-07 Tim COTE Topical compositions comprising pentoxifylline and methods of treatment using the same
FR3090385B1 (fr) * 2018-12-21 2021-01-08 Pf Medicament Composition émolliente sous forme d’émulsion
CN111743853A (zh) * 2019-03-29 2020-10-09 天津金耀集团有限公司 一种近中性丁酸氢化可的松的外用药物组合物
EP4192431A1 (en) 2020-08-04 2023-06-14 Venthera, Inc. Formulations of phosphoinositide 3-kinase inhibitors
US20220202841A1 (en) * 2020-12-24 2022-06-30 Erine A. Kupetsky Dermatological formulations for treatment of dermatitis

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3969516A (en) 1974-12-19 1976-07-13 Nelson Research & Development Company Composition and method for treatment of acne
US4497794A (en) 1980-12-08 1985-02-05 Dermik Laboratories, Inc. Erythromycin/benzoyl peroxide composition for the treatment of acne
US4361584A (en) 1977-10-07 1982-11-30 A.H.C. Pharmacal, Inc. Composition and method for the treatment of acne
US4247547A (en) 1979-03-19 1981-01-27 Johnson & Johnson Tretinoin in a gel vehicle for acne treatment
US4387107A (en) 1979-07-25 1983-06-07 Dermik Laboratories, Inc. Stable benzoyl peroxide composition
US4692329A (en) 1980-12-08 1987-09-08 William H. Rorer, Inc. Erythromycin/benzoyl peroxide antiacne compositions
LU83173A1 (fr) 1981-02-27 1981-06-05 Oreal Nouvelles compositions cosmetiques pour le traitement des cheveux et de la peau contenant une poudre resultant de la pulverisation d'au moins une plante et un agent de cohesion
US4514385A (en) 1981-10-05 1985-04-30 Alcon Laboratories, Inc. Anti-acne compositions
CH643138A5 (de) * 1983-08-29 1984-05-30 Mepha Ag Indomethacin enthaltende, gelartige salbe.
LU85111A1 (fr) 1983-12-01 1985-09-12 Oreal Composition anti-acnetique a base de peroxyde de benzoyle et d'au moins un filtre solaire
US5446028A (en) 1985-12-12 1995-08-29 Dermik Laboratories, Inc. Anti-acne method and composition
FR2604357B1 (fr) 1986-09-30 1988-12-02 Oreal Composition pharmaceutique et cosmetique anti-acneique
AU618517B2 (en) 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
WO1988006888A1 (en) * 1987-03-20 1988-09-22 Curatek Pharmaceuticals, Inc. Novel topical metronidazole formulations and therapeutic uses thereof
MY105521A (en) * 1989-04-17 1994-10-31 Healthpoint Ltd Moisturizing vehicle for topical application of vitamin a acid.
US5721275A (en) 1989-06-07 1998-02-24 Bazzano; Gail S. Slow release vehicles for minimizing skin irritancy of topical compositions
US5122519A (en) * 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
GB9021320D0 (en) 1990-10-01 1990-11-14 Diomed Dev Ltd Compositions for topical application
US5380528A (en) 1990-11-30 1995-01-10 Richardson-Vicks Inc. Silicone containing skin care compositions having improved oil control
DE69208098T2 (de) * 1991-10-16 1996-08-08 Richardson Vicks Inc Wässeriges,kosmetisches gel,mit niedrigem ph,das nichtionogene polyacrylamidderivate enthält
JP3190441B2 (ja) * 1992-07-20 2001-07-23 エーザイ株式会社 塩酸アゼラスチンを含有する安定な製剤
US5549914A (en) * 1992-12-14 1996-08-27 Sween Corporation Heat stable wound care gel
SK279919B6 (sk) 1993-07-01 1999-05-07 Yamanouchi Europe B.V. Farmaceutický a kozmetický prostriedok na miestne
US5482710A (en) 1993-07-30 1996-01-09 Chesebrough-Pond'usa Co., Division Of Conopco, Inc. Cosmetic composition for treatment of pimples and redness
US5382432A (en) 1993-11-15 1995-01-17 Elizabeth Arden Company, Division Of Conopco, Inc. Cosmetic method for treatment of skin
US5466446A (en) 1994-02-16 1995-11-14 Stiefel Laboratories, Inc. Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof
US5538732A (en) 1994-04-12 1996-07-23 Creative Products Resource, Inc. Medicated applicator sheet for topical drug delivery
US5451405A (en) 1994-04-25 1995-09-19 Chesebrough-Pond's Usa Co. Skin treatment composition
US5445823A (en) 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
AT408067B (de) 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
EP0738510A3 (fr) 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
US5750122A (en) 1996-01-16 1998-05-12 The Procter & Gamble Company Compositions for treating hair or skin
JP3193617B2 (ja) * 1996-01-29 2001-07-30 カネボウ株式会社 清涼感付与剤および人体用組成物
US5891451A (en) 1996-06-25 1999-04-06 Elizabeth Arden Company, Division Of Conopco, Inc. Skin treatment with salicylic acid esters
FR2753626B1 (fr) * 1996-09-20 1998-11-06 Centre International De Rech Dermatologiques Galderma Cird Galderma Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant
JPH1179948A (ja) * 1997-09-12 1999-03-23 Noevir Co Ltd 養毛剤及び毛髪用化粧料、並びに皮脂分泌抑制用皮膚外用剤
US6083996A (en) * 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition

Also Published As

Publication number Publication date
ZA200301037B (en) 2004-02-09
RU2251410C2 (ru) 2005-05-10
HK1125847A1 (en) 2009-08-21
CA2417646C (en) 2010-05-04
CY1114646T1 (el) 2016-12-14
AU2001279002B2 (en) 2006-04-27
DE60138549D1 (de) 2009-06-10
PL213237B1 (pl) 2013-01-31
AU7900201A (en) 2002-02-18
FR14C0053I1 (fr) 2014-08-08
PT1304992E (pt) 2009-07-20
EP1304992B1 (en) 2009-04-29
CY2014005I1 (el) 2014-07-02
KR20030057526A (ko) 2003-07-04
JP2004505900A (ja) 2004-02-26
SI1304992T1 (sl) 2009-10-31
SI2052714T1 (sl) 2013-11-29
ATE429922T1 (de) 2009-05-15
BE2013C060I2 (es) 2020-12-15
PL360589A1 (en) 2004-09-06
EP1304992A4 (en) 2006-11-02
MXPA03001006A (es) 2005-02-25
US6387383B1 (en) 2002-05-14
ES2326955T3 (es) 2009-10-22
CY1109189T1 (el) 2014-07-02
CN1460013B (zh) 2011-12-14
CY2014005I2 (el) 2015-12-09
JP4988129B2 (ja) 2012-08-01
CA2417646A1 (en) 2002-02-14
WO2002011683A1 (en) 2002-02-14
CN101305982A (zh) 2008-11-19
EP2052714A1 (en) 2009-04-29
US6517847B2 (en) 2003-02-11
EP2052714B1 (en) 2013-09-04
DK1304992T3 (da) 2009-08-10
BR0113247A (pt) 2003-06-24
KR100840169B1 (ko) 2008-06-23
CN101305982B (zh) 2011-12-14
PT2052714E (pt) 2013-10-17
US20020176891A1 (en) 2002-11-28
DK2052714T3 (da) 2013-10-14
EP1304992A1 (en) 2003-05-02
CN1460013A (zh) 2003-12-03
ES2437321T3 (es) 2014-01-10
LU92401I2 (fr) 2014-05-19
KR20080036246A (ko) 2008-04-25

Similar Documents

Publication Publication Date Title
AR030093A1 (es) Sistema para la distribucion topica del gel
KR101689898B1 (ko) 광선 각화증을 치료하기 위한 국소 조성물
AR048017A1 (es) Composicion y metodo para aumentar la biodisponibilidad
KR930021210A (ko) 레티노이드 수성 겔 조성물
RU2493847C2 (ru) Фармацевтические составы для местного применения, содержащие низкую концентрацию бензоилпероксида в суспензии в воде и смешивающимся с водой органическом растворителе
BR0009213A (pt) Processos e composições para tratamento de tumores sólidos
RU2008114352A (ru) Композиции для местного применения
BR9909796B1 (pt) "derivados de piperidinopirimidina para aplicação tópica"
AR021539A1 (es) Preparaciones topicas anhidras para la piel
CR7614A (es) Preparaciones de insulina acida con estabilidad mejorada
ES2160239T3 (es) Composicion farmaceutica filmogena para la administracion transdermica.
AR033808A1 (es) Una composicion topica de anestesia local y los parches y los envases que la contienen
ES2133000T3 (es) Composicion cosmetica y/o dermatologica que contiene al menos un precursor de agente activo y un poli(acido 2-acrilamido 2-metilpropano sulfonico) reticulado.
CO5440227A1 (es) Composicion antihelmitica e inyectable mejorada de crecimiento
EP0331489A2 (en) Acne treatment
AR041021A1 (es) Composicion topica
AR026569A1 (es) Auxiliar humectante concentrado pobre en espuma, su empleo y procedimiento para su elaboracion
AR012217A1 (es) Una composicion topica para mejorar la penetracion de compuestos farmaceuticos
UY29342A1 (es) Composicione antihelmintica
ES2124983T5 (es) Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
PE20131337A1 (es) Composicion anestesica nanoparticulada para la administracion topica
AR033312A1 (es) Composicion que consta de un agonista alfa-2 adrenergico y un acido graso
AR040747A1 (es) Un sistema de suministro percutaneo
JP2007197445A (ja) ３つ以上の活性成分を投薬するためのディスペンサー
AR034554A1 (es) Un metodo para mejorar la distribucion de un ingrediente activo en un licor de curtido, una tableta o bloque para ser usado en dicho metodo, y el uso de dicha tableta o bloque en el curtido de cuero

Legal Events

Date Code Title Description
FC Refusal